期刊文献+

特比萘芬与氟康唑或伊曲康唑体外联合抗白念珠菌的作用 被引量:7

In vitro interaction of terbinafine with fluconazole or itraconazole against Candida albicans
暂未订购
导出
摘要 目的探讨特比萘芬与氟康唑或伊曲康唑体外联合抗白念珠菌的作用。方法采用微量液体稀释法测定特比萘芬、氟康唑、伊曲康唑对生殖器部位分离的36株白念珠菌药敏试验,应用棋盘微量稀释法测定特比萘芬与氟康唑或伊曲康唑对36株白念珠菌的联合药敏试验。结果白念珠菌菌株对氟康唑、伊曲康唑、特比萘芬耐药株分别为3株(8.33%)、4株(11.11%)、6株(16.67%)。特比萘芬和氟康唑联用M IC几何平均数较其单独应用均显著降低(t=3.590,P<0.05;t=3.252,P<0.05),15株有协同作用(42%),18株有相加作用(50%),3株无关作用(8%);特比萘芬和伊曲康唑联用后的M IC几何平均数较其单独应用均显著降低(t=3.849,P<0.001;t=2.409,P<0.05),表现为协同作用有14株(39%),相加作用的有17株(47%),无关作用的有5株(14%);均未发现拮抗作用。结论特比萘芬与氟康唑或伊曲康唑联合应用对大部分白念珠菌能产生协同作用和相加作用,提示特比萘芬与氟康唑或伊曲康唑联合应用能增强抗白念珠菌的作用。 Objective To investigate the interaction between terbinafine and fluconazole or itraconazole against Candida albicans. Methods The minimum inhibitory concentrations (MIC) of 36 clinical isolates of Candida albicans from genital locus was determined by broth microdilution method recommended by NCCLS. A checkerboard microdilution method was used to study the in vitro interaction of terbinafine with fluconazole or itraconazole. Results The incidence of Candida albicans resistant isolates were 8.33% (fluconazole), 11.11% (itraconazole) and 16.67% (terbinalfine). The geometric mean MIC of terbinafine combinated with fluconazole was significantly lower than that of the single agent (t=3.590, P〈0.05; t=3.25, P〈0.05). Forty-two percent (15/36) of interactions were synergy, fifty percent (18/36) additive, and eight percent (3/36) indifferent. Terbinafine in combination with itraconazole significantly reduced the geometric mean MIC than the single agent (t=3.849, P〈0.001; t=2.409, P〈0.05). 39% (14/36) of interactions weresynergy, 47% (17/36) were additive, and 14% (5/36) were indifferent. Antagonism was not observed in any drug combination. Conclusions The combination of terbinafine with either fluconazole or itraconazole can produce synergism and /or addition in most strains of Candida albicans in vitro.
出处 《中国抗生素杂志》 CAS CSCD 北大核心 2005年第9期568-571,共4页 Chinese Journal of Antibiotics
关键词 白念珠菌 氟康唑 伊曲康唑 特比萘芬 Candida albicans Terbinafine Fluconazole Itraconazole
  • 相关文献

参考文献14

  • 1韩旭东,张永信,章强强.白色念珠菌对氟康唑耐药性的诱导和回复研究[J].中国抗生素杂志,2004,29(6):374-377. 被引量:10
  • 2National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved Standard M27-A [S]. Wayne, PA: NCCLS,1997,17(9):1.
  • 3Mosquera J, Sharp A, Moore C B, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.[J]. J Antimicrob Chemother, 2002,50(2) : 189.
  • 4Perea S, Gonzalez G, Annette W, et al. In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azole[J]. J Clin Microbiol,2002,40(5) : 1831.
  • 5王洪生,骆志成,武三卯,薛小云,周小黎.外阴阴道念珠菌病患者阴道念珠菌对抗真菌药物的敏感性测量[J].临床皮肤科杂志,2002,31(6):346-348. 被引量:6
  • 6Czaika V, Tietz H J, Schmalreck A, et al. Antifungal susceptibility testing in chronically recurrent vaginal candidiasis as basis for effective therapy [J]. Mycoses,2000,43(Suppl 2) :45.
  • 7Evans E G. Resistance of Candida species to antifungal agent used in the treatment of onychomycosis : a review of current problems [J]. Br J Dermatol, 1999, 141 (Suppl 56):33.
  • 8Te Dorsthorst D T, Verweij P E, Meis J F, et al. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals againt itraconazole-susceptible and -resistant Aspergillus fumigatus isolates[J].Antimicrob Agents Chemother , 2002,46 (3) : 702.
  • 9Weig M, Muller F M. Synergism of voriconazole and terbinafine against Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis[J]. Antimicrob Agents chemother, 2001, 45(3):966.
  • 10肖异珠,李桂明.尼克霉素Z与氟康唑或特比萘芬抗白念珠菌的体外实验[J].中华皮肤科杂志,2001,34(5):379-379. 被引量:14

二级参考文献15

  • 1赵辩.临床皮肤病学(第一版)[M].南京:江苏科技出版社,2001.127-128.
  • 2Li R K,Antimicrob Agents Chemother,1999年,43卷,1401页
  • 3吕桂霞,中华皮肤科杂志,1999年,32卷,309页
  • 4Law D, Moore C B, Wardle H M, et al. High prevalence of antifungal resistance in Candida spp from patients with AIDS [J]. J Antimicrob Chemother,1994,34(5):659
  • 5Chavanet P, Lopez J, Grappin M, et al. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients [J]. AIDS,1994,8(7):945
  • 6National committee for clinical laboratory standards. Referenced method for broth dilution antifungal susceptibility testing of yeasts [M]. Approved standard M27-A. Pennsylvania: NCCLs, 1997,17(9):1
  • 7Pfaller M A, Jones R N, Messer S A, et al. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program [J]. Diagn Microbiol Infect Dis,1998,31(1):327
  • 8Viudes A, Peman J, Canton E, et al. Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death [J]. Eur J Clin Microbiol Infect Dis,2002,21(11):767
  • 9McGuire W, Clerihew L, Austin N. Prophylactic intravenous antifungal agents to prevent mortality and morbidity in very low birth weight infants [J]. Cochrane Database Syst Rev,2003,(1):CD00385
  • 10Bow E J, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients:a meta analysis of randomized-controlled clinical trials [J]. Cancer,2002,94(12):3230

共引文献27

同被引文献37

  • 1滕小玉,管忠震,姚志文,刘冬耕,周宁宁,罗汉钰,Michael Hawkins,Patrick Soon-Shiong.晚期实体癌患者对不含聚氧乙烯蓖麻油注射用紫杉醇白蛋白纳米粒悬浮液的临床耐受性研究[J].癌症,2004,23(z1):1431-1436. 被引量:39
  • 2贺志彬,廖万清,徐红,温海.微量稀释法检测氟康唑和伊曲康唑对白念珠菌的敏感性[J].中国中西医结合皮肤性病学杂志,2005,4(2):71-73. 被引量:5
  • 3沈亮亮,叶元康.氟康唑与5-氟胞嘧啶体外联合抗白念珠菌临床分离株的研究[J].同济大学学报(医学版),2005,26(6):19-21. 被引量:10
  • 4张良珂,侯世祥,卢懿,宋相容.叶酸受体介导米托蒽醌白蛋白纳米粒的体内分布及药效学研究[J].中国药学杂志,2007,42(9):676-678. 被引量:10
  • 5National Committee for Clinical Laboratory standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27 - A. National Committee for Clinical Laboratory standards, Wayne, Pa NCCLS, 1997,17 (9) : 1.
  • 6Ghannoum MA, Elewski B. Successful treatment of fluconazole - resistant oropharyngeal candidiasis by a combination of fluconazole and terbinafine. Clin Diagn Lab Immunol 1999 ; 6 (6) : 921 - 923.
  • 7Michael Weig, Frank - Michael C. Synergism of voriconazole and terbinafine against eandida albieans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2001 ;45(3) :966 - 968.
  • 8National Conunittee for Clinical Laboratory standards. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved Standard M27 - A. National Committee for Clinical Laboratory standards Wayne Pa. NCCLS 1997 ; 17(9) : 1.
  • 9Mosquera J, Sharp A, Moore CB, et al. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp. J Antimicrob Chemother 2002; 50(2) : 189.
  • 10Wroblewska MM, Swoboda-Kopec E, Rokosz A, et al. Epidemiolo- gy of clinical isolates of Candida albicans and their susceptibility to triazoles [ J ]. Int J Antimicrob Agents, 2002,20 ( 6 ) : 472 475.

引证文献7

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部